[Search for an optimal therapy of patients with atrial fibrillation (results of many years of comparison of three treatment strategies).].
Patients with nonrheumatic atrial fibrillation (n=465, mean age 59.4+/-3.8 years) received controlled therapy for 7.4+/-1.6 years. Group 1 comprised 306 patients with paroxysmal and persistent atrial fibrillation who after restoration of sinus rhythm received antiarrhythmic therapy aimed at prevention of recurrences and repetitive cardioversions. Group 2 consisted of 67 similar patients who did not receive continuous antiarrhythmic therapy. Therapy of patients with persistent atrial fibrillation (group 3, n=92) included heart rate slowing drugs and anticoagulants. Group 1 was characterized by lowest rate of complications and all cause mortality, and best quality of life. There were more nonfatal strokes in group 2. All cause mortality in group 2 was 15% (p<0.05). Highest rate of nonfatal strokes, and deaths due to chronic heart failure was observed in group 3. All cause mortality in this group was 22.8% (p<0.001 vs group 1).
Kanorskiĭ
S G
SG
Kuban State Medical Academy; Krasnodar City Center of Critical Medicine; Regional Diagnostic Center.
Medvedeva
I V
IV
Mel'nik
M G
MG
Shevelev
V I
VI
Kanorskaia
Iu S
IuS
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation; D004554:Electric Countershock; D006801:Humans; D011788:Quality of Life
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants